Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (6)
  • Open Access

    REVIEW

    Side effect management algorithms for niraparib/abiraterone acetate in prostate cancer

    Jean-Baptiste Lattouf1, Jenny J. Ko2, Margot K. Davis3, Christian Constance4, Geoffrey T. Gotto5

    Canadian Journal of Urology, Vol.31, No.5, pp. 11977-11985, 2024

    Abstract Introduction: Niraparib, a PARP1/2 inhibitor, is newly approved in combination with abiraterone acetate (AA) plus prednisone or prednisolone (niraparib/AA+P) for the treatment of adult patients with BRCA-mutated, treatment-naïve metastatic castration resistant prostate cancer (mCRPC). Detailed guidance beyond the prescribing information may be helpful in managing the side effect profile and dosing practicalities of this combination therapy.
    Materials and methods: A panel of specialists convened to design management algorithms for four common niraparib/ AA+P treatment-related adverse events (AEs) in mCRPC; anemia, thrombocytopenia, hypertension, and nausea. The algorithms build on Health Canada-approved prescribing information to highlight practical considerations related… More >

  • Open Access

    ARTICLE

    Exploring the Prevalence and Contributing Factors of Depression among Sickle Cell Anemia Patients in Saudi Arabia’s Jazan Region

    Abdullah A. Alharbi1, Ahmad Y. Alqassim1,*, Mohammed A. Muaddi1, Najat H. Aldubayyan1, Rana I. Abuhadi1, Futon A. Akoor1, Sarah J. Mobarki1, Imtenan A. Oberi1, Ghaidaa H. Alharbi1, Yara Ajeebi1, Adnan M. Alkhayat2, Hafiz Malhan3, Mohammed Bakkar4, Anwar M. Makeen1

    International Journal of Mental Health Promotion, Vol.26, No.5, pp. 351-359, 2024, DOI:10.32604/ijmhp.2024.047219 - 30 May 2024

    Abstract Sickle Cell Anemia (SCA) is a prevalent genetic condition in Saudi Arabia, particularly in the Jazan region. The study’s purpose was to assess the prevalence of de-pression among individuals with SCA in this area and to identify the factors associated with this condition. The study involved 391 adult participants, all patients in the hematology center of Prince Mohammed bin Nasser Hospital (PMNH). Data was collected through an anonymous interview questionnaire–the Arabic version of the Patient Health Questionnaire-9 (PHQ-9)–between March–May 2022. The questionnaire covered socio-demographic information and variables related to the participant’s SCA history, such as… More >

  • Open Access

    ARTICLE

    DTL facilitates the Fanconi anemia pathway for ultraviolet-induced DNA repair in retinal pigment epithelial cells

    JIUCHUN GUO1, JIE PAN2,*, QIANQIAN GUO2

    BIOCELL, Vol.46, No.2, pp. 505-510, 2022, DOI:10.32604/biocell.2021.015785 - 20 October 2021

    Abstract The excessive energy of light, especially the invisible rays with lower wavelength, is basically absorbed by retinal pigment epithelium (RPE) and usually causes DNA damage. The molecular mechanism behind DNA damage repair response to this frequent stress in RPE is not clearly understood. In this study, we determined that the Fanconi anemia (FA) pathway was activated in human RPE ARPE-19 cells after ultraviolet (UV) B and C treatment. Moreover, immunoprecipitation (IP) of FANCD2 indicated that denticleless E3 ubiquitin protein ligase homolog (DTL) closely interacted with FANCD2. Knockdown of DTL weakened the activity of the FA More >

  • Open Access

    ARTICLE

    Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy

    Takashi Saito*†, Atsuo Okamura, Junichiro Inoue, Daisuke Makiura, Hisayo Doi§, Kimikazu Yakushijin, Hiroshi Matsuoka, Yoshitada Sakai†#, Rei Ono*

    Oncology Research, Vol.27, No.4, pp. 469-474, 2019, DOI:10.3727/096504018X15267574931782

    Abstract Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n=9; diffuse large B-cell lymphoma; n=31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range=27–76 years). Statistical More >

  • Open Access

    ARTICLE

    Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition

    Bijan Keikhaei1, Ali Reza Mohseni2, Reza Norouzirad3, Mastaneh Alinejadi4, Somayeh Ghanbari1, Fariba Shiravi1, Ghasem Solgi5

    European Cytokine Network, Vol.24, No.1, pp. 45-52, 2013, DOI:10.1684/ecn.2013.0328

    Abstract Objective: This study aimed to evaluate serum levels of pro-inflammatory cytokines and TGF-β in sickle cell disease (SCD) patients, and to compare the results during vaso-occlusive crisis (VOC) or steady state (StSt) conditions. Methods: 54 SCD patients (37HbSS and 17Sβ+Thal) were enrolled in the study and evaluated in two groups as follows; group A consisted of 39 VOC patients and group B comprised 15 StSt patients. Nineteen healthy volunteers were included as controls. Circulating levels of IL-1, IL-6, IL-8, IL-17,TNF-α and TGF-β were measured using ELISA. Results: Patients in VOC showed higher mean levels of all… More >

  • Open Access

    ARTICLE

    How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?

    Richard Choo1,2, Sarat Chander1,3, Cyril Danjoux1, Gerard Morton1, Andrew Pearce1, Gerrit Deboer1, Ewa Szumacher1, Andrew Loblaw1, Patrick Cheung1, Tony Woo1

    Canadian Journal of Urology, Vol.12, No.1, pp. 2547-2552, 2005

    Abstract Purpose: To examine the change of hemoglobin in relation to testosterone level in non-metastatic prostate cancer patients receiving 2-year androgen suppression.
    Methods and materials: A cohort of 72 patients, as participants of a phase II study, were treated with adjuvant radiotherapy plus 2-year androgen suppression after surgery to reduce the risk of relapse. Patients had laboratory tests including hemoglobin (Hb) and testosterone, and a quality of life questionnaire at regular intervals during the androgen suppression and post-androgen suppression period. The pattern of the change in Hb was evaluated in relation to testosterone level. The clinical significance of… More >

Displaying 1-10 on page 1 of 6. Per Page